STRATA Skin Sciences, Inc.

DB:E2OM Stock Report

Market Cap: €16.9m

STRATA Skin Sciences Past Earnings Performance

Past criteria checks 0/6

STRATA Skin Sciences's earnings have been declining at an average annual rate of -19.7%, while the Medical Equipment industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 4.5% per year.

Key information

-19.7%

Earnings growth rate

-16.5%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate4.5%
Return on equity-85.4%
Net Margin-32.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How STRATA Skin Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:E2OM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2333-11231
30 Sep 2335-7241
30 Jun 2336-7251
31 Mar 2337-6261
31 Dec 2236-6251
30 Sep 2235-6251
30 Jun 2233-6251
31 Mar 2231-3231
31 Dec 2130-3231
30 Sep 2128-2211
30 Jun 2126-3202
31 Mar 2122-6181
31 Dec 2023-4171
30 Sep 2025-4181
30 Jun 2027-4191
31 Mar 2031-3221
31 Dec 1932-4221
30 Sep 1931-3211
30 Jun 1931-3211
31 Mar 1931-3201
31 Dec 1830-4191
30 Sep 1831-9201
30 Jun 1830-22191
31 Mar 1831-21192
31 Dec 1732-22192
30 Sep 1730-18172
30 Jun 1731-6182
31 Mar 1730-4192
31 Dec 1631-3202
30 Sep 1633-3232
30 Jun 1633-14243
31 Mar 1626-22222
31 Dec 1518-28192
30 Sep 159-34152
30 Jun 151-24111
31 Mar 151-15111
31 Dec 141-16112
30 Sep 141-14112
30 Jun 141-19132
31 Mar 140-27143
31 Dec 131-26164
30 Sep 131-27165
30 Jun 130-25165

Quality Earnings: E2OM is currently unprofitable.

Growing Profit Margin: E2OM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: E2OM is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.

Accelerating Growth: Unable to compare E2OM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: E2OM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-9.8%).


Return on Equity

High ROE: E2OM has a negative Return on Equity (-85.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.